Los Angeles Capital Management LLC Sells 100 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Los Angeles Capital Management LLC reduced its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 1.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,884 shares of the company’s stock after selling 100 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Krystal Biotech were worth $1,799,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in KRYS. Swiss National Bank lifted its holdings in shares of Krystal Biotech by 0.8% in the first quarter. Swiss National Bank now owns 36,200 shares of the company’s stock valued at $6,441,000 after purchasing an additional 300 shares in the last quarter. Sei Investments Co. boosted its position in Krystal Biotech by 128.3% during the 1st quarter. Sei Investments Co. now owns 33,752 shares of the company’s stock worth $6,005,000 after acquiring an additional 18,968 shares during the last quarter. ProShare Advisors LLC grew its stake in shares of Krystal Biotech by 9.0% during the 1st quarter. ProShare Advisors LLC now owns 5,865 shares of the company’s stock worth $1,044,000 after acquiring an additional 486 shares in the last quarter. State Board of Administration of Florida Retirement System grew its stake in shares of Krystal Biotech by 18.5% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 7,307 shares of the company’s stock worth $1,300,000 after acquiring an additional 1,140 shares in the last quarter. Finally, Scout Investments Inc. acquired a new stake in shares of Krystal Biotech in the first quarter valued at approximately $8,976,000. 86.29% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the sale, the insider now directly owns 1,500,882 shares in the company, valued at $296,814,424.32. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 14.10% of the stock is owned by company insiders.

Krystal Biotech Stock Down 1.6 %

KRYS opened at $184.22 on Thursday. Krystal Biotech, Inc. has a 12-month low of $96.73 and a 12-month high of $219.34. The business has a 50 day moving average of $181.31 and a 200-day moving average of $181.36. The stock has a market cap of $5.30 billion, a price-to-earnings ratio of 104.08 and a beta of 0.82.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, November 4th. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.84 by $0.07. The firm had revenue of $83.84 million during the quarter, compared to analysts’ expectations of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The company’s revenue for the quarter was up 879.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.67) earnings per share. As a group, analysts expect that Krystal Biotech, Inc. will post 2.97 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently weighed in on KRYS. Stifel Nicolaus raised their target price on shares of Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. Evercore ISI lifted their target price on Krystal Biotech from $201.00 to $206.00 and gave the company an “outperform” rating in a research report on Monday, August 12th. William Blair upgraded Krystal Biotech to a “strong-buy” rating in a report on Friday, August 30th. Chardan Capital raised their price target on Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a research note on Monday, August 5th. Finally, Citigroup upped their price objective on Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $197.00.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).